Design, synthesis and anticancer evaluation of novel arylhydrazones of active methylene compounds

Akshaya Murugesan, Saravanan Konda Mani, Shabnaz Koochakkhani, Kumar Subramanian, Jayalakshmi Kandhavelu, Ramesh Thiyagarajan, Atash V. Gurbanov, Kamran T. Mahmudov, Meenakshisundaram Kandhavelu

    Tutkimustuotos: ArtikkeliScientificvertaisarvioitu

    1 Sitaatiot (Scopus)
    15 Lataukset (Pure)

    Abstrakti

    Nerve growth factor (NGF) and its receptor, tropomyosin kinase receptor kinase type A (TrkA) is emerging as an important target for Glioblastoma (GBM) treatment. TrkA is the cancer biomarker majorly involved in tumor invasion and migration into nearby normal tissue. However, currently, available Trk inhibitors exhibit many adverse effects in cancer patients, thus demanding a novel class of ligands to regulate Trk signaling. Here, we exploited the role of TrkA (NTRK1) expression from the 651 datasets of brain tumors. RNA sequence analysis identified overexpression of NTRK1 in GBM, recurrent GBM as well in Oligoastrocytoma patients. Also, TrkA expression tends to increase over the higher grades of GBM. TrkA protein targeting hydrazone derivatives, R48, R142, and R234, were designed and their mode of interaction was studied using molecular docking and dynamic simulation studies. Ligands' stability and binding assessment reveals R48, 2 2-(2-(2-hydroxy-4-nitrophenyl) hydrazineylidene)-1-phenylbutane-1,3-dione, as a potent ligand that interacts well with TrkA's hydrophobic residues, Ile, Phe, Leu, Ala, and Val. R48- TrkA exhibits stable binding potentials with an average RMSD value <0.8 nm. R48 obeyed Lipinski's rule of five and possessed the best oral bioavailability, suggesting R48 as a potential compound with drug-likeness properties. In-vitro analysis also revealed that R48 exhibited a higher cytotoxicity effect for U87 GBM cells than TMZ with the IC50 value of 68.99 μM. It showed the lowest percentage of cytotoxicity to the non-cancerous TrkA expressing MEF cells. However, further SiRNA analysis validates the non-specific binding of R48, necessitating structural alteration for the development of R48-based TrkA inhibitor for GBM therapeutics.

    AlkuperäiskieliEnglanti
    Artikkeli127909
    Sivumäärä9
    JulkaisuInternational Journal of Biological Macromolecules
    Vuosikerta254
    NumeroPart 3
    Varhainen verkossa julkaisun päivämäärämarrask. 2023
    DOI - pysyväislinkit
    TilaJulkaistu - tammik. 2024
    OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

    Julkaisufoorumi-taso

    • Jufo-taso 1

    !!ASJC Scopus subject areas

    • Structural Biology
    • Biochemistry
    • Molecular Biology

    Sormenjälki

    Sukella tutkimusaiheisiin 'Design, synthesis and anticancer evaluation of novel arylhydrazones of active methylene compounds'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

    Siteeraa tätä